We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
WAINUA AstraZeneca Pty Ltd
Product name
WAINUA
Sponsor
Accepted date
Jun-2025
Active ingredients
eplontersen sodium
Proposed indication
Wainua (eplontersen) is for the treatment of transthyretin-mediated amyloidosis (ATTRv) in adults. ATTRv causes amyloid deposits in various organs, potentially leading to organ damage and failure.
Application type
A (new medicine)
Publication date
Jun-2025